Compare CVS Health Corp (CVS) vs Rocket Lab USA Inc (RKLB) Price & Performance

CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.

CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.

Rocket Lab (RKLB) trades at $81.30, up 1.57% in the last session, with a bullish technical outlook and strong analyst support. The stock is near its pivot point of $79, with resistance at $82. Fundamentally, revenue grew 62% year-over-year in Q2 2026 to a record $601.80 million, but the company remains unprofitable with a net income margin of -26.87%. Recent news highlights the Neutron rocket's upcoming launch and a $2.36 billion backlog, though margin pressures and cash burn are concerns.

The outlook is mixed: analysts project 76% buy ratings and a $118.00 price target, signaling confidence in growth from launch demand and contracts. However, high valuation (P/S of 60.8), persistent losses, and execution risks around Neutron's timeline pose significant downside. Investors should weigh growth potential against profitability challenges and competitive pressures in the space sector.